CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

HONG KONG, Oct 7, 2021 – (ACN Newswire via SEAPRWire.com) – ACT Genomics Holdings Co. Ltd. (“ACT Genomics” or “the Group”) announced today that CerbACT Asia (Taipei, Taiwan), a Cerba Research and ACT Genomics joint venture, had unveiled its new purpose-built facility to empower precision medicine for better patient outcomes. The opening ceremony of CerbACT […]

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

HONG KONG, Sep 17, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (HKEX 3681.HK, “SinoMab”) announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. (“Sinovent”) today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, “Everest”) to out-license the right to develop and commercialize SN1011 (referred as “XNW1011” by Sinovent), […]

Kintor Pharma Announces 2021 Interim Results

SUZHOU, CHINA, Aug 30, 2021 – (ACN Newswire via SEAPRWire.com) – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities […]

Apollomics, Inc. Doses First Patient in Phase I Clinical Trial of APL-102

Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced […]

Apollomics, Inc. Doses First Patient in A Phase I Clinical Trial of APL-102

Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced […]

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

TOKYO, Jul 27, 2021 – (JCN Newswire via SEAPRWire.com) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer’s disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer’s Association […]

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021

TOKYO, Jul 21, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at […]

Premier of South Australia Launches $1.5m Vaccine and Immunobiology State-of-the art Laboratory for APAC Clinical Trials

ADELAIDE, AUS, July 14, 2021 – (ACN Newswire) – Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around […]

Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures

NEW JERSEY and HANGZHOU, CHINA, Jul 15, 2021 – (ACN Newswire via SEAPRWire.com) – Adlai Nortye Ltd. (hereinafter referred to as “Adlai Nortye”), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. Co-led by SDIC Fund Management and Tigermed, this round of financing […]

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

ADELAIDE, AUS, Jul 9, 2021 – (ACN Newswire via SEAPRWire.com) – The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial. Tetherex Pharmaceuticals, Inc. is a privately held, clinical […]

Avance Clinical Appoints Asia Biotech Specialist to Support APAC Growth

ADELAIDE, AUS, June 28, 2021 – (ACN Newswire) – Avance Clinical, the leading Australian CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient, announced the appointment of Andy Hu as Business Development Manager APAC, to support increasing biotech clinical trial demand from the region. Andy Hu Formerly with Informa Pharma Intelligence, the international biopharma […]

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

TOKYO, Jun 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer’s disease (AD). Breakthrough Therapy designation is an FDA program […]

Avance Clinical’s USA Biotech Survey Finds 21% Not Aware Australian Clinical Data is Accepted by the FDA and Other Major Regulatory Authorities

ADELAIDE, AUS, Jun 4, 2021 – (ACN Newswire via SEAPRWire.com) – The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical announced the results of their Australian Clinical Trials Knowledge Survey with Endpoints News as part of their presence at BIO Digital 2021. Results from the survey […]

Agilex Biolabs Partners with Endpoints News on Deconvoluting Inflammation and Immunology for Clinical Trials

ADELAIDE, AUS, May 21, 2021 – (ACN Newswire via SEAPRWire.com) – Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials is partnering with Endpoints News to share the latest on deconvoluting inflammation and immunology for clinical trials, in a webinar hosted by Endpoints News Editor Arsalan Arif. Agilex Biolabs’ Director, […]

Agilex Biolabs’ Toxicology Tapped for SARS-CoV-2 Vaccine Research

ADELAIDE, AUS, May 17, 2021 – (ACN Newswire via SEAPRWire.com) – Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia. TetraQ is a NATA-accredited, GLP-recognised rodent […]

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand

ADELAIDE, AUS, May 7, 2021 – (ACN Newswire via SEAPRWire.com) – The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. Avance Clinical is accredited as […]